Amgen Inc (AMGN): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.5%. By the end of trading, Amgen fell $1.26 (-1.1%) to $111.92 on average volume. Throughout the day, 2,769,675 shares of Amgen exchanged hands as compared to its average daily volume of 3,214,400 shares. The stock ranged in price between $111.50-$113.27 after having opened the day at $112.08 as compared to the previous trading day's close of $113.19. Other companies within the Drugs industry that declined today were: China Botanic Pharmaceutical ( CBP), down 96.4%, Achillion Pharmaceuticals ( ACHN), down 58.3%, Mast Therapeutics ( MSTX), down 40.1% and Cellular Dynamics International ( ICEL), down 14.3%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $86.5 billion and is part of the health care sector. Shares are up 33.2% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, GW Pharmaceuticals PLC ADR ( GWPH), up 93.1%, Zalicus ( ZLCS), up 23.7%, Bacterin International Holdings ( BONE), up 11.6% and Delcath Systems ( DCTH), up 9.6% , were all gainers within the drugs industry with Regeneron Pharmaceuticals ( REGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

Cramer vs. Chaikin: Amgen -- Be Careful of This Stock

The Shifting Price Action Continued Today

The Shifting Price Action Continued Today

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)

Get Ready for Volatility Now: Cramer's 'Mad Money' Recap (Monday 1/29/18)